Physician profile
Jackie L Stringfellow
NPI 1386625200
$3,731.85
in general payments reported to CMS, 2019-2025
36 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $368 · 2021: $864 · 2022: $654 · 2023: $431 · 2024: $561 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $943.93 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $568.14 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $356.39 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $240.84 | 2021-2025 | |
| Lilly USA, LLC | $225.33 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $221.15 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $156.23 | 2020-2025 | Shingrix, Arexvy |
| Pfizer INC. | $124.70 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.26 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.23 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.82 | 2019-2022 | |
| Abbott Laboratories | $69.72 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $58.16 | 2025 | Rexulti |
| Eisai INC. | $35.24 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $34.73 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $34.30 | 2024-2025 | |
| Antares Pharma, INC. | $33.62 | 2021-2022 | |
| Dexcom, INC. | $32.00 | 2023-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $26.02 | 2020-2021 | |
| Axsome Therapeutics, INC. | $24.68 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $23.33 | 2019 | |
| Amarin Pharma, INC. | $21.30 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.12 | 2024 | Caplyta |
| Exact Sciences Corporation | $17.94 | 2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $17.84 | 2019 | |
| Sanofi Pasteur INC. | $16.87 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.19 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.00 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.27 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.57 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.95 | 2022 | |
| Medtronic, INC. | $13.95 | 2021 | |
| Ibsa Pharma INC. | $13.67 | 2024 | Licart, Tirosint |
| Biogen, INC. | $12.51 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.61 | 2020 | |
| Phathom Pharmaceuticals, INC. | $9.24 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Stringfellow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.